SPECIAL NOTICE
A -- Study titled: Cross-Species Immune System Reference
- Notice Date
- 3/14/2013
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- OPTION-1115619
- Archive Date
- 4/12/2013
- Point of Contact
- Sean Wybenga, Phone: 301-827-6761
- E-Mail Address
-
sean.wybenga@fda.hhs.gov
(sean.wybenga@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- This synopsis is hereby issued in accordance with FAR Part 5.203 and FAR Part 17.207 in response to the mandatory requirement for a 15 day notification. The purpose of this synopsis is to announce the Food and Drug Administration's intent to exercise an option to Leland Junior Stanford University to procure continued research and development services for a study titled, "Cross-Species Immune System Reference." The contract was solicited and awarded through Broad Agency Announcement No. FDABAA-12-00118. The objective of the proposed work to be conducted is to use mass cytometry to map immune responses in an expanded number of human and animal samples that result from various stimuli (including biological threat agents and candidate medical countermeasures). The expanded project will also include the comparison of samples collected from animals infected with biological threat agents to previously described work conducted with samples from uninfected animals, as well as studies performed with inactivated biological threat agents. As with the work performed in the base period, the human and animal responses will be compared and the resulting data will be made available to the community through an open-access resource. It is anticipated that this work will enhance the understanding of the diversity of immune responses elicited by these stimuli both within and across species. Specifically, the project provides a potential means to better understand the mechanism(s) of toxicity of biological threat agents, identify off-target effects of candidate medical countermeasures, the mechanism(s) of action for candidate medical countermeasures, and the comparability of these effects between animals and humans. The incorporation of studies with biothreat agents may also provide new insight into pathogenesis and identification of biomarkers. Any questions regarding this synopsis should be directed to Sean Wybenga, Contract Specialist, via email at Sean.Wybenga@hhs.fda.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/OPTION-1115619/listing.html)
- Record
- SN03012370-W 20130316/130314235412-d7fbc2fc0a883fea12c2f7df23b52cc5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |